Canaccord analyst Edward Nash raised the firm’s price target on Madrigal Pharmaceuticals to $336 from $296 and keeps a Buy rating on the shares. The target increase was mainly due to a shorter discount period with 2029 being the out-year of our model.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDGL:
- Madrigal Pharmaceuticals price target raised to $300 from $250 at Oppenheimer
- Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
- Madrigal Pharmaceuticals reports Q4 EPS ($4.98), consensus ($4.56)
- Looking for Powerful Healthcare Stocks? These 5 Made Enormous Profit in 2022
- Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences